The duration of acute lymphoblastic leukemia, or acute lymphoblastic leukemia, varies from person to person and cannot be generalized, but is mainly related to factors such as clinical typing, age of onset of the disease, time of diagnosis and treatment, and the patient’s physical condition. Generally speaking, the earlier the disease is detected, diagnosed and treated, the better the prognosis and the longer the survival time of the patient. Moreover, due to the use of multiple combination chemotherapy regimens, the strengthening of supportive therapy and the prevention of central nervous system leukemia in recent years, the survival time of acute lymphoblastic leukemia has been extended and its prognosis has been significantly improved. Specific drugs include cyclophosphamide, desmethoxazole erythromycin, and methotrexate. Overall, pediatric patients who are treated aggressively after their first diagnosis have a higher rate of complete remission than the first complete remission rate in adults, and a higher 5-year survival rate than adults. Therefore, after the diagnosis of acute lymphoblastic leukemia, patients should actively receive regular and complete treatment under the guidance of physicians, and some patients may be able to obtain a better prognosis and prolong the survival time.